Gemtuzumab ozogamicin. Treatment of acute myeloid leukemia

Drugs of the Future

Volumn 25, Issue 7, 2000, Pages 686-692

  Rabasseda, X ^a   Graul, A ^a   Castaner, R M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 6 HYDROXYMETHYLACYLFULVENE; 7 HYDROXYSTAUROSPORINE; ALEMTUZUMAB; ANNAMYCIN; ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; BRYOSTATIN 1; CALICHEAMICIN DERIVATIVE; CDP 771; DOLASTATIN 10; EXATECAN; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; HUM 195; IMMUNOTOXIN LMB2; IODINE 131; IODINE DERIVATIVE; LINTUZUMAB; MAXAMINE; NELARABINE; OBLIMERSEN; PIPERANOMETOZINE; PR 1; RETINOIC ACID; SODIUM PHENYLBUTYRATE; TIPIFARNIB; TROXACITABINE; UNCLASSIFIED DRUG; VALSPODAR; WAY CMA 676;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; FETOTOXICITY; FEVER; HUMAN; MUCOSA INFLAMMATION; NONHUMAN;

EID: 0033801515     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.07.587004     Document Type: Article

References (24)

1. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
2. Calicheamicin derivatives conjugated to monoclonal antibodies: Determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry
3. Treatment of acute myelogenous leukemia in older adults
4. Treatment of relapsed and refractory acute myelogenous leukemia
5. Anti-CD33 calicheamicin hybrid conjugates for the treatment of acute myelogenous leukemia
6. Monoclonal antibodies to the myeloid stem cells: Therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate
7. Preparation of monoclonal antibody-calicheamicin conjugates
8. A population pharmacokinetic analysis of gemtuzumab zogamicin: A new antibody chemotherapeutic agent
9. Dose escalation phase I study of recombinant engineered human anti-CD33 antibody-calicheamicin drug conjugate (CMA-676) in patients with relapsed or refractory acute myeloid leukemia (AML)
10. Selective ablation of acute myeloid leukemia using an anti-CD33 calicheamicin immunoconjugate
11. Emerging clinical experience with CMA-676 in relapsed AML
12. Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse
13. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
14. Preliminary results of the efficacy and safety of CMA-676 in patients with AML in first relapse
15. Comparison of the efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients < 60 and equal to or more than 60 years of age with AML in first relapse
16. Short-term outcomes after treatment for relapsed acute myeloid leukemia (AML): A comparison of recent gemtuzumab ozogamicin (gem070, also known as CMA-676) clinical trial data and historical control data